Business Practice

That which we call rosaimab by any other name would find regulatory approval and commercial success. Or would it?

An industry consortium is tackling one of pharma’s biggest drug-related challenges.

Sitting Down With Dolores Schendel, Chief Executive Officer and Chief Scientific Officer at Medigene.

IFPMA’s Director-General, Thomas Cueni, outlines how companies worldwide can foster long-term tech transfer partnerships.

The Russian invasion of Ukraine will disrupt and displace a great deal of work in drug discovery. Here’s why.

It’s time for pharma companies to embrace digital technologies.

We talk to Roche’s Paulo Fontoura about Evrysdi and its impact on patient lives.

In this new series, we ask industry leaders in the cell and gene field to answer key questions about the industry.

2022 is well underway, and with it comes The Medicine Maker Company of the Year Awards. Our old faithful Power List is back too.

How will the pharmaceutical landscape shape up in 2022? Industry experts share their predictions.